You are here

The Galien Foundation Debuts 2019 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Medical Technology" Categories

NEW YORK, July 15, 2019 /PRNewswire/ -- The Galien Foundation today announced the 2019 Annual Prix Galien USA Award nominees. Counted among the global health innovation industry's most prized honors, the Prix Galien Award recognizes outstanding biomedical and medical technology product achievement that improves the human condition.

To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for marketing within the last five years and demonstrate significant potential to advance human health worldwide. Sales data are not considered by the nominating committee in their award nominee selection; innovative science and health impact is paramount.

"We are blessed to live in a time of exciting scientific, medical and technological advances that promise a revolution in cures, treatments and tools for patients everywhere," said Dr. Sue Desmond-Hellmann, chair of the Prix Galien USA Awards Committee and CEO of the Bill & Melinda Gates Foundation. "The 2019 nominees demonstrate this incredible potential across multiple platforms and reflect the abundance of new science that underpins the Galien Foundation's mission to improve the human condition."

The Prix Galien USA 2019 nominees include products evaluated in the following categories: "Best Biotechnology Product," with 17 nominees; "Best Pharmaceutical Product" with 22 nominees; and "Best Medical Technology," 17 nominees. 

Nominees include the first FDA-approved drugs using RNA interference technology and targeted mutation gene therapy; the first of a new line of 'tissue agnostic' cancer-fighting drugs; an entirely new class of female contraceptives, designed for use in resource-limited settings; novel inhalation devices that enhance dosing accuracy against major chronic conditions like asthma and COPD; the first FDA-approved therapy for endometriosis pain in more than a decade; the first in a new class of anti-epileptic drugs and first prescription product derived from the cannabis plant; and the first prescription digital therapeutic to address the opioid abuse crisis through interactive engagement between patient and clinician.

Best Biotechnology Product (Nominees)

Aimovig® (erenumab-aooe)

Amgen Inc.


Portola Pharmaceuticals, Inc.


Regeneron & Sanofi


Stemline Therapeutics, Inc.


Eli Lilly & Co.


Amicus Therapeutics


Genentech, Inc.

LUXTURNA™ (voretigene neparvovec-rzyl)

Spark Therapeutics


Alnylam Pharmaceuticals


Dompé Pharmaceuticals


BioMarin Pharmaceutical Inc


Leadiant Biosciences, Inc.




Janssen Research & Development, LLC


Takeda Pharmaceutical Company Limited


Akcea Therapeutics and Ionis Pharmaceuticals

ULTOMIRIS® (ravulizumab-cwvz)

Alexion Pharmaceuticals, Inc.


Best Pharmaceutical Product (Nominees)


Population Council


Pfizer Inc.


GW Pharmaceuticals plc/Greenwich Biosciences Inc.


Janssen Research & Development, LLC

Gamifant® (emapalumab-lzsg)


INGREZZA® (valbenazine) capsules

Neurocrine Biosciences, Inc.


Boehringer Ingelheim Pharmaceuticals, Inc.


Pfizer Inc.


AstraZeneca PLC; Innate Pharma SA


Advanced Accelerator Applications USA, Inc.


Medicines Development for Global Health


AbbVie Inc.

Pifeltro™ and Delstrigo™

Merck & Co., Inc.


Merck & Co., Inc.


Mitsubishi Tanabe Pharma America, Inc.


Aerie Pharmaceuticals, Inc.


SIGA Technologies, Inc.


Melinta Therapeutics, Inc.




Pfizer Inc. and Astellas Pharma

YUPELRI® (revefenacin) Inhalation Solution

Theravance Biopharma, Inc.


TESARO, a GSK Company


Best Medical Technology (Nominees)

rhPDGF-BB Technology*

*Augment® Injectable Bone Graft; Augment® Bone Graft; GEM® Growth-factor Enhanced Matrix; Regranex Gel

Lynch Biologics, LLC

AXIOS™ Stent and Electrocautery Enhanced Delivery System

Boston Scientific Corp., Inc.


Clinical Research Consultants, Inc. and HumanOptics AG

FreeStyle® Libre 14 Day Flash Glucose Monitoring System


GentleWave® System


HeartLogic™ Heart Failure Diagnostic

Boston Scientific Corp., Inc.

Implantable System for Remodulin®

Medtronic plc


Edwards Lifesciences Corporation

iStent inject®

Glaukos Corporation

Magtrace® and Sentimag® Magnetic Localization System


Medtronic DBS Therapy for Epilepsy

Medtronic Brain Modulation

PK Papyrus Covered Coronary Stent System


ProAir® Digihaler™

Teva Pharmaceutical Industries

reSET® and reSET-O®

Pear Therapeutics

Sentinel™ Cerebral Protection System

Boston Scientific Corp., Inc.

Starkey Livio® AI

Starkey Hearing Technologies

Zephyr Endobronchial Valve System


"The nominees selected by our independent committee reflect how drug, device and delivery technologies are converging to offer more options for people, especially those with untreatable conditions, along with the ability to make products more effective and convenient for those who need them most, including for the aged, children and women," said Bruno Cohen, Chairman of the Galien Foundation.  "In addition to all the great science, it reflects progress in the global movement for health equity, which is also central to our mission to improve the human condition.  Thus, it is both timely and proper that our gathering on October 24 will celebrate the achievements of these researchers and innovators, whose work represents the next chapter of human progress in fighting disease."

The Prix Galien USA Committee is composed of 12 renowned leaders from the biomedical industry and academia, including four Nobel Laureates, who together are responsible for evaluating nominees. Winners will be announced during the Prix Galien USA Awards Ceremony on October 24, 2019 at the American Museum of Natural History in New York City.  Registration to attend the 2019 Prix Galien Awards Ceremony can be accessed at

Prix Galien Awards Committee 2019

Susan DESMOND-HELLMANN, M.D., M.P.H, Chief Executive Officer of the Bill & Melinda Gates Foundation; Committee Chair

Richard AXEL, M.D., Nobel Laureate, Co-Director, Kavli Institute for Brain Science, Columba University Medical Center, NYC, NY 

Michael S. BROWN, M.D., Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

Laurie GLIMCHER, M.D., CEO and President, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School, Cambridge, MA

Joseph GOLDSTEIN, M.D., Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, University of Texas, Southwestern Medical Center, Dallas, TX

Robert LANGER, Sc.D., David H. Koch Institute Professor, MIT, Cambridge, MA

Cato T. LAURENCIN, M.D., PhD., University Professor, University of Connecticut, Storrs, CT

Paul A. MARKS, M.D., Laboratory Head of Cell Biology and President Emeritus, Memorial Sloan Kettering Cancer Center, NYC, NY

Michael ROSENBLATT, M.D., Chief Medical Officer, Flagship Pioneering Inc, Cambridge, MA

Bengt SAMUELSSON, M.D., Ph.D., Nobel Laureate, Former President, Karolinska Institute; Former Chairman, Nobel Foundation 

Marc TESSIER-LAVIGNE, Ph.D., President, Stanford University, Palo Alto, CA

P. Roy VAGELOS, M.D., Retired Chairman and CEO, Merck & Co.; Chairman of the Board, Regeneron Pharmaceuticals, Inc.; Committee Chairman (2012-2017)

About the Galien Foundation

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to catalyze the development of the next generation of innovative treatments and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies.  The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology.  Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

For more information, visit

Galien Foundation Media Contact:
Kara Bradley
Finn Partners
646 213 7243

Cision View original content to download multimedia:

SOURCE The Galien Foundation